To investigate the mechanisms by which endogenous BMPR2 is degraded in the context of PAH, PAECs were treated with the lysosomal inhibitors BafA1 and HCQ and with the proteasome inhibitors MG‐132 and BTZ. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.